Table 1.
Clinical, treatment and survival characteristics of the 21 patients with CD20-negative diffuse large B-cell lymphoma
| Patient NO. | Age, y/Sex | HIV status | PS score | Site of involvement | Stage | Bulky disease | Serum LDH | IPI | Therapy and response for initial therapy | Out come | Survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
68/M |
- |
1 |
LN |
IIB |
No |
Normal |
1 |
CHOP × 6+RT, ICE × 4,CR |
AWD |
117 |
| 2 |
33/F |
- |
1 |
Cervical |
IA |
No |
Normal |
0 |
CHOP × 4, CR |
AND |
117 |
| 3 |
49/F |
- |
1 |
Maxillary sinus, LN |
IIB |
No |
Normal |
0 |
CHOP × 5, DHAP × 4, CR |
DOD |
11 |
| 4 |
11/M |
- |
2 |
Spinal canal, Retroperitoneal |
IIIB |
Yes |
Normal |
3 |
Surgical resection+RT, CAV × 2 + BFM-90 × 1, PD |
DOD |
23 |
| 5 |
37/M |
- |
1 |
Retroperitoneal, LN, BM |
IVB |
Yes |
Elevated |
2 |
CHOP × 2,VAD × 2,MEA × 2, PR |
AND |
90 |
| 6 |
56/M |
- |
1 |
Stomach, Retroperitoneal, |
IIB |
No |
Normal |
0 |
CHOP × 6,ICE × 2,DHAP × 3, GEMOX × 7,Auto PBSCT, PR |
DOD |
33 |
| 7 |
54/F |
- |
1 |
Stomach |
IIB |
Yes |
Normal |
0 |
Gastrectomy, CHOP × 6,ICE × 2, EPOCH × 1,FC × 1, PD |
DOD |
13 |
| 8 |
73/M |
- |
1 |
LN |
IA |
No |
Elevated |
2 |
CHOP × 2, PD |
DOD |
7 |
| 9 |
44/M |
- |
1 |
LN |
IIIA |
No |
Elevated |
2 |
CHOP × 6,HD-MTX +Ara-C × 1, PD |
DOD |
6 |
| 10 |
41/M |
- |
2 |
Stomach, LN |
IIA |
No |
Elevated |
1 |
CHOP × 2, PD |
DOD |
3 |
| 11 |
66/M |
- |
1 |
Stomach, LN |
IIB |
Yes |
Elevated |
2 |
EPOCH × 6+RT, CR |
AND |
27 |
| 12 |
22/M |
- |
1 |
Liver, lung, LN, hip |
IVB |
No |
Elevated |
3 |
CHOP × 1,DHAP × 2, IMVP-16 × 4, PD |
DOD |
13 |
| 13 |
55/M |
- |
1 |
LN |
IA |
No |
Normal |
0 |
Bortezomib+EPOCH × 4, RT, CR |
AND |
25 |
| 14 |
19/F |
- |
1 |
Stomach, LN |
IIA |
Yes |
Normal |
0 |
Gastrectomy, CHOP × 6, CR |
AND |
20 |
| 15 |
67/M |
- |
1 |
Spleen, LN |
IIIA |
No |
Elevated |
3 |
CHOP × 1, ICE × 4,SD |
AWD |
19 |
| 16 |
47/F |
- |
1 |
Ileum, liver, LN, |
IVA |
Yes |
Normal |
2 |
Surgical resection, CHOP × 1, MAID × 2,GEMOX × 4,ESHAP × 2, PD |
DOD |
12 |
| 17 |
27/M |
- |
1 |
Mediastinum, pleural |
IIA |
Yes |
Normal |
0 |
Surgical resection, CHOP+IT × 6, CR |
AND |
15 |
| 18 |
83/M |
- |
1 |
Lung, rib, LN |
IVA |
No |
Normal |
3 |
CHOP × 3, GEMOX × 2, CR |
DOD |
7 |
| 19 |
53/M |
- |
1 |
Stomach, LN |
IIIA |
No |
Normal |
1 |
CHOPE × 6,GIFOX × 2,GND × 2, CR |
AND |
9 |
| 20 |
67/M |
- |
1 |
LN |
IA |
No |
Normal |
1 |
RT,CHOP × 2,Ara-C+DXM × 1, Ara-C+Paclitaxel × 1, PR |
AWD |
9 |
| 21 | 71/M | - | 2 | Kidney, sternum, vertebral, BM | IVA | Yes | Normal | 3 | CHOP × 2, ICE × 2, PR | DOD | 7 |
Note: -, negative; +, positive; PS, performance status; LN, lymph node; BM, bone marrow; LDH, lactate dehydrogenase; IPI, International Prognostic Index; RT, radiotherapy; CAV, cyclophosphamide, doxorubicin, vincristine; VAD, vincristine, doxorubicin, dexamethasone; MEA, mitoxantrone, etoposide, cytarabine; GEMOX, gemcitabine, oxaliplatin; GIFOX, gemcitabine, ifosfamide, oxaliplatin; GND, gemcitabine, vinorelbine, doxil; DXM, dexamethasone; MAID, mesna, doxorubicin, ifosfamide, dacarbazine; PBSCT, peripheral blood stem cell transplant; IT, intrathecal; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.